cellmid
News    Contact Us
Site Search:
home
  • About Us
    • Directors & Management
    • Scientists
    • Corporate Governance
      • Board Charter
      • Code of Conduct
      • Share Trading Policy
      • Audit Committee Charter
      • Continuous Disclosure Policy
      • Risk Management Policy
      • Performance Evaluation Process
      • Corporate Code of Conduct
    • Careers
  • Technology
    • Diagnostic
      • Human
      • Veterinary
    • Therapeutics
      • CAB101 Inflammatory Disease
      • CAMI103 Heart attack
    • Key Publications
      • Full List of Publications
    • Key Patents
  • Pipeline
    • Product Pipeline
    • Market Potential
  • New Products
    • Midkine ELISA Kit
    • Advangen International Hair Loss Products
    • Evolis Products
  • Shareholder Information
    • Public Disclosure Policy
    • ASX Company Announcements
    • Financial Information & Reports
    • Share Registry Information
    • Annual General Meeting
    • Analyst Coverage
    • Share Information
  • Midkine Conference
    • 2012 Program
    • Conference Venue
    • Accommodation
    • Contact Conference Committee
    • 2010 Conference wrap up
      • Gallery
      • 2010 Program
back to news list »
Sydney, Monday 13 February 2012

Cellmid Limited (ASX: CDY) advises that it has signed an agreement with La Jolla Cove Investors to terminate the Funding Agreement dated September 2010.

Click here to read more »

© 2011 Cellmid Ltd. All rights reserved. ABN 69 111 304 119
Share Trading Policy | Privacy Policy | Contact Us | Site Map
Netstarter - Ecommerce Web Design on Magento
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##